ClinicalTrials.gov
public full text
Public Domain
Pomaglumetad Effects on Glutamate Biomarkers
The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression#845190
- Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation#1102352
- A Study Of New Medicine (GSK 372475) For The Treatment Of Depression#1185353
- Effects of Seven Day Prucalopride Administration in Healthy Volunteers#1229892
- Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects#844974
Record · ID 1408572
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive